OnCo
drugsProductNot mapped hereapproved

Methotrexate

The 1948 antifolate that produced the first chemotherapy remissions in childhood leukaemia and the first cure of a solid tumour; still essential in ALL, lymphoma, osteosarcoma and CNS lymphoma.

Farber (1948) with aminopterin; methotrexate cured choriocarcinoma (1956). Roles: ALL maintenance and CNS prophylaxis (intrathecal), high-dose regimens in osteosarcoma (MAP), PCNSL and Burkitt/DLBCL CNS prophylaxis, GTN, head and neck and bladder (MVAC). Toxicities: mucositis, nephrotoxicity (high dose; glucarpidase rescue), hepatotoxicity, pneumonitis. Also the standard DMARD in rheumatoid arthritis and used in ectopic pregnancy.

Loading structure…
|
Methotrexate
PubChem
Modality
Antifolate (DHFR inhibitor)
Mechanism
Inhibits dihydrofolate reductase, depleting tetrahydrofolate needed for thymidylate and purine synthesis; high doses with leucovorin rescue cross the blood-brain barrier.
Brand / code
Trexall / Otrexup / Xatmep
Medicare
Part B or Part D

Oral anticancer drug with an injectable equivalent used for the same indication, so Medicare covers the oral form under Part B (the oral anticancer drug benefit) as well as under Part D; the pharmacy bills whichever applies. High-dose IV methotrexate is Part B and usually inpatient (Part A).

Commercial insurance
covered on label

Multi-source generic on low-cost tiers; usually no prior authorisation. Cash prices without insurance are modest.

Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.

Not appraisedSearch NICE
Notes
Long-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
NHS England
Routinely funded for the appraised indication (or via managed access)

Sources: NICE search: methotrexate. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.

Regulatory

1top

Approvals

RegionYearIndication
US1953ALL, choriocarcinoma, and later osteosarcoma, breast, head and neck, lung, lymphoma, mycosis fungoides

Trials

top

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
Methotrexate
intervention: Methotrexate
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this drug: (TITLE:"Methotrexate" OR ABSTRACT:"Methotrexate" OR TITLE:"Trexall" OR ABSTRACT:"Trexall" OR TITLE:"Otrexup" OR ABSTRACT:"Otrexup" OR TITLE:"Xatmep" OR ABSTRACT:"Xatmep") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Methotrexate, not a curated reading list.

Connected

18top